Cystatin C may be biomarker to predict survival, disease progression
Elevated blood levels of the Cystatin C protein are significantly associated with faster disease progression and shorter survival in people…
Articles by Andrea Lobo, PhD
Coya to meet with FDA about a Phase 2 trial of COYA 302 for ALS
Coya Therapeutics is planning to file a request with the U.S. Food and Drug Administration (FDA) to continue testing…
New platform may help to ID cognitive problems in ALS
A new home-based neurocognitive platform from Cumulus Neurosciences is feasible to use and patient-friendly, and shows potential to identify…
Phase 1 clinical trial of QRL-201 for ALS approved in the UK
An ongoing Phase 1 clinical trial of QurAlis’ experimental therapy QRL-201 in people with amyotrophic lateral sclerosis (ALS)…
Clinical trial of oral ALS therapy SPG302 is enrolling in Australia
Spinogenix has launched a clinical trial in Australia to investigate its amyotrophic lateral sclerosis (ALS) treatment candidate SPG302…
1st healthy volunteer dosed in trial of potential ALS therapy VTX3232
The first healthy volunteer has been dosed in a Phase 1 clinical trial evaluating VTX3232, Ventyx Biosciences’ investigational oral…
BenevolentAI candidate BEN-34712 to go to late-stage preclinical studies
BenevolentAI is advancing BEN-34712, its experimental oral therapy for amyotrophic lateral sclerosis (ALS), to late-stage preclinical studies. The studies…
Phase 1 trial of QRL-201 to open for patients at sites across Europe
QurAlis soon expects to open its ongoing Phase 1 clinical trial testing QRL-201 in people with amyotrophic…
Modulo Bio’s goal: Better understand and treat ALS, like diseases
Modulo Bio has launched with $8 million in funding and a goal to map the neuroimmune system and…
FDA final approval decision on NurOwn for ALS due by year’s end
A final decision by the U.S. Food and Drug Administration (FDA) on whether or not to approve NurOwn for…